Most Read Articles
07 Sep 2019
Eating mushrooms has no correlation with biomarkers and risks of cardiovascular disease (CVD) and type 2 diabetes (T2D) in adults, a US study has shown.
03 Sep 2019
Sleep apnoea is highly prevalent but largely undetected in the general population of middle-aged adults, with a symptom-based strategy proving to be useless for specific diagnosis, according to a recent study. Moreover, mild sleep apnoea represents a higher-risk phenotype with manifestly increased metabolic, inflammatory and cardiovascular risk factor burden, with potential public health implications.
Rachel Soon, 2 days ago

Adding simvastatin as an adjuvant to standard triple therapy in Helicobacter pylori treatment may help compensate for increasing antimicrobial resistance, according to a new study.

Christina Lau, 03 Sep 2019
The sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin significantly reduces the risk of death and hospitalization in patients with heart failure (HF) with reduced ejection fraction (rEF) regardless of whether they have type 2 diabetes mellitus (T2DM), the DAPA-HF trial has shown.

Regular yogurt intake lowers risk of incident hypertension

17 Jul 2018
Yogurt: Key to reducing high blood pressure

Higher total intake of dairy products, especially yogurt, may help reduce the risk of incident hypertension in middle-aged and older adult men and women, suggests a recent study.

The investigators examined the association between yogurt consumption, as well as cheese, milk and total dairy, and high blood pressure in two Nurses’ Health Study cohorts (NHS; n=69,298), NHS II (n=84,368) and the Health Professional Follow-up Study (HPFS; n=30,512). Participants from NHS, NHS II and HPFS were followed for incident hypertension for up to 30, 20 and 24 years, respectively.

Time-dependent multivariate-adjusted Cox proportional hazards models were used to calculate hazard ratios, while pooled risk estimates were derived from fixed effects meta-analysis.

Participants from NHS, NHS II and HPFS who consumed at least five servings of yogurt per week (vs <1 serving per month) had 19-percent (95 percent CI, 0.75–0.87), 17-percent (0.77–0.90) and 6-percent (0.83–1.07) lower risks of hypertension, respectively.

Pooled analyses revealed an association between higher yogurt consumption and 16-percent (0.80–0.88) lower hypertension risk, while higher total dairy (3 to <6 vs <0.5 servings/day), milk (2 to <6/day vs <4/week) and cheese (1–4/day vs <1/week) correlated with 16-percent (0.81–0.87), 12-percent (0.86–0.90) and 6-percent (0.90–0.97) lower hypertension risks, respectively.

Adjustment for body mass index as a possible causal intermediate showed that total dairy, yogurt, milk and cheese were associated with 13-percent, 10-percent, 8-percent and 8-percent lower risks of incident hypertension, respectively.

Higher yogurt intake plus higher DASH (Dietary Approach to Stop Hypertension) diet scores correlated with 30-percent (0.66–0.75) reduced hypertension risk compared with lower levels of both factors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
07 Sep 2019
Eating mushrooms has no correlation with biomarkers and risks of cardiovascular disease (CVD) and type 2 diabetes (T2D) in adults, a US study has shown.
03 Sep 2019
Sleep apnoea is highly prevalent but largely undetected in the general population of middle-aged adults, with a symptom-based strategy proving to be useless for specific diagnosis, according to a recent study. Moreover, mild sleep apnoea represents a higher-risk phenotype with manifestly increased metabolic, inflammatory and cardiovascular risk factor burden, with potential public health implications.
Rachel Soon, 2 days ago

Adding simvastatin as an adjuvant to standard triple therapy in Helicobacter pylori treatment may help compensate for increasing antimicrobial resistance, according to a new study.

Christina Lau, 03 Sep 2019
The sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin significantly reduces the risk of death and hospitalization in patients with heart failure (HF) with reduced ejection fraction (rEF) regardless of whether they have type 2 diabetes mellitus (T2DM), the DAPA-HF trial has shown.